Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
Identifieur interne : 003B06 ( Ncbi/Merge ); précédent : 003B05; suivant : 003B07Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
Auteurs : Eliza M. Govender [Afrique du Sud] ; Leila E. Mansoor [Afrique du Sud] ; Quarraisha Abdool Karim [Afrique du Sud]Source :
- AIDS care [ 1360-0451 ] ; 2017.
Descripteurs français
- KwdFr :
- Acceptation des soins par le patient, Adolescent, Adulte, Adulte d'âge moyen, Agents antiVIH (usage thérapeutique), Auto-efficacité, Comportement sexuel, Femelle, Gels, Humains, Infections à VIH (), Jeune adulte, Population des banlieues, Population rurale, Population urbaine, Prophylaxie pré-exposition, République d'Afrique du Sud, Ténofovir (usage thérapeutique).
- MESH :
- usage thérapeutique : Agents antiVIH, Ténofovir.
- Acceptation des soins par le patient, Adolescent, Adulte, Adulte d'âge moyen, Auto-efficacité, Comportement sexuel, Femelle, Gels, Humains, Infections à VIH, Jeune adulte, Population des banlieues, Population rurale, Population urbaine, Prophylaxie pré-exposition, République d'Afrique du Sud.
English descriptors
- KwdEn :
- Adolescent, Adult, Anti-HIV Agents (therapeutic use), Female, Gels, HIV Infections (prevention & control), Humans, Middle Aged, Patient Acceptance of Health Care, Pre-Exposure Prophylaxis, Rural Population, Self Efficacy, Sexual Behavior, South Africa, Suburban Population, Tenofovir (therapeutic use), Urban Population, Young Adult.
- MESH :
- chemical , therapeutic use : Anti-HIV Agents, Tenofovir.
- prevention & control : HIV Infections.
- Adolescent, Adult, Female, Gels, Humans, Middle Aged, Patient Acceptance of Health Care, Pre-Exposure Prophylaxis, Rural Population, Self Efficacy, Sexual Behavior, South Africa, Suburban Population, Urban Population, Young Adult.
Abstract
Young women bear a disproportionately high burden of HIV infection in sub-Saharan Africa, prioritising pre-exposure prophylaxis (PrEP) can be an integral part of HIV prevention combination strategies. Women initiated HIV prevention technology options will require consistent adherence, an imperative for product effectiveness. With several PrEP clinical trials underway; exploring women's acceptability to advances in HIV prevention technologies can better facilitate demand creation for future PrEP roll out. This study utilised the opportunity of post-trial access to CAPRISA 008 women (trial) and non-trial women from three geo-spatial settings (urban, rural and peri-urban) to identify microbicide acceptability and how product associations of microbicides can influence future HIV prevention choices. Six participatory workshops using participatory action research with art-based activities and discussion groups were conducted in KwaZulu-Natal with 104 women from various geo-spatial locations and social status to understand microbicide acceptability and product associations. The data were analysed using thematic analysis. The study found that women's acceptability and product association of the tenofovir gel microbicide differed according to rural and urban areas. Most urban women identified confidence, sexiness and classiness as key associations that will encourage microbicide acceptability and use, while rural women identified respect, responsibility and confidence as the key product associations, with increased focus on the individual and collective family/community benefits of product acceptance and use. Urban-rural differences suggest a market segmentation that is contextualised to be locally responsive to promote HIV prevention technologies. Various sexual encounters further determined the types of HIV prevention technologies women would consider. In line with WHO's recommendation that PrEP should be an additional prevention choice for people at risk of HIV, this study underscores the importance of user engagement, understanding product associations and how this can influence product acceptability and promotion of HIV prevention technologies.
DOI: 10.1080/09540121.2016.1248349
PubMed: 27799005
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000842
- to stream PubMed, to step Curation: 000842
- to stream PubMed, to step Checkpoint: 000842
Links to Exploration step
pubmed:27799005Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.</title><author><name sortKey="Govender, Eliza M" sort="Govender, Eliza M" uniqKey="Govender E" first="Eliza M" last="Govender">Eliza M. Govender</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban </wicri:regionArea><wicri:noRegion>Durban </wicri:noRegion></affiliation></author><author><name sortKey="Mansoor, Leila E" sort="Mansoor, Leila E" uniqKey="Mansoor L" first="Leila E" last="Mansoor">Leila E. Mansoor</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban </wicri:regionArea><wicri:noRegion>Durban </wicri:noRegion></affiliation></author><author><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban </wicri:regionArea><wicri:noRegion>Durban </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27799005</idno><idno type="pmid">27799005</idno><idno type="doi">10.1080/09540121.2016.1248349</idno><idno type="wicri:Area/PubMed/Corpus">000842</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000842</idno><idno type="wicri:Area/PubMed/Curation">000842</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000842</idno><idno type="wicri:Area/PubMed/Checkpoint">000842</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000842</idno><idno type="wicri:Area/Ncbi/Merge">003B06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.</title><author><name sortKey="Govender, Eliza M" sort="Govender, Eliza M" uniqKey="Govender E" first="Eliza M" last="Govender">Eliza M. Govender</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban </wicri:regionArea><wicri:noRegion>Durban </wicri:noRegion></affiliation></author><author><name sortKey="Mansoor, Leila E" sort="Mansoor, Leila E" uniqKey="Mansoor L" first="Leila E" last="Mansoor">Leila E. Mansoor</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban </wicri:regionArea><wicri:noRegion>Durban </wicri:noRegion></affiliation></author><author><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name><affiliation wicri:level="1"><nlm:affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban </wicri:regionArea><wicri:noRegion>Durban </wicri:noRegion></affiliation></author></analytic><series><title level="j">AIDS care</title><idno type="eISSN">1360-0451</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Anti-HIV Agents (therapeutic use)</term><term>Female</term><term>Gels</term><term>HIV Infections (prevention & control)</term><term>Humans</term><term>Middle Aged</term><term>Patient Acceptance of Health Care</term><term>Pre-Exposure Prophylaxis</term><term>Rural Population</term><term>Self Efficacy</term><term>Sexual Behavior</term><term>South Africa</term><term>Suburban Population</term><term>Tenofovir (therapeutic use)</term><term>Urban Population</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acceptation des soins par le patient</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents antiVIH (usage thérapeutique)</term><term>Auto-efficacité</term><term>Comportement sexuel</term><term>Femelle</term><term>Gels</term><term>Humains</term><term>Infections à VIH ()</term><term>Jeune adulte</term><term>Population des banlieues</term><term>Population rurale</term><term>Population urbaine</term><term>Prophylaxie pré-exposition</term><term>République d'Afrique du Sud</term><term>Ténofovir (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Tenofovir</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Ténofovir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Female</term><term>Gels</term><term>Humans</term><term>Middle Aged</term><term>Patient Acceptance of Health Care</term><term>Pre-Exposure Prophylaxis</term><term>Rural Population</term><term>Self Efficacy</term><term>Sexual Behavior</term><term>South Africa</term><term>Suburban Population</term><term>Urban Population</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acceptation des soins par le patient</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Auto-efficacité</term><term>Comportement sexuel</term><term>Femelle</term><term>Gels</term><term>Humains</term><term>Infections à VIH</term><term>Jeune adulte</term><term>Population des banlieues</term><term>Population rurale</term><term>Population urbaine</term><term>Prophylaxie pré-exposition</term><term>République d'Afrique du Sud</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Young women bear a disproportionately high burden of HIV infection in sub-Saharan Africa, prioritising pre-exposure prophylaxis (PrEP) can be an integral part of HIV prevention combination strategies. Women initiated HIV prevention technology options will require consistent adherence, an imperative for product effectiveness. With several PrEP clinical trials underway; exploring women's acceptability to advances in HIV prevention technologies can better facilitate demand creation for future PrEP roll out. This study utilised the opportunity of post-trial access to CAPRISA 008 women (trial) and non-trial women from three geo-spatial settings (urban, rural and peri-urban) to identify microbicide acceptability and how product associations of microbicides can influence future HIV prevention choices. Six participatory workshops using participatory action research with art-based activities and discussion groups were conducted in KwaZulu-Natal with 104 women from various geo-spatial locations and social status to understand microbicide acceptability and product associations. The data were analysed using thematic analysis. The study found that women's acceptability and product association of the tenofovir gel microbicide differed according to rural and urban areas. Most urban women identified confidence, sexiness and classiness as key associations that will encourage microbicide acceptability and use, while rural women identified respect, responsibility and confidence as the key product associations, with increased focus on the individual and collective family/community benefits of product acceptance and use. Urban-rural differences suggest a market segmentation that is contextualised to be locally responsive to promote HIV prevention technologies. Various sexual encounters further determined the types of HIV prevention technologies women would consider. In line with WHO's recommendation that PrEP should be an additional prevention choice for people at risk of HIV, this study underscores the importance of user engagement, understanding product associations and how this can influence product acceptability and promotion of HIV prevention technologies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27799005</PMID><DateCreated><Year>2016</Year><Month>11</Month><Day>01</Day></DateCreated><DateCompleted><Year>2017</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1360-0451</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>AIDS care</Title><ISOAbbreviation>AIDS Care</ISOAbbreviation></Journal><ArticleTitle>Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.</ArticleTitle><Pagination><MedlinePgn>734-740</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/09540121.2016.1248349</ELocationID><Abstract><AbstractText>Young women bear a disproportionately high burden of HIV infection in sub-Saharan Africa, prioritising pre-exposure prophylaxis (PrEP) can be an integral part of HIV prevention combination strategies. Women initiated HIV prevention technology options will require consistent adherence, an imperative for product effectiveness. With several PrEP clinical trials underway; exploring women's acceptability to advances in HIV prevention technologies can better facilitate demand creation for future PrEP roll out. This study utilised the opportunity of post-trial access to CAPRISA 008 women (trial) and non-trial women from three geo-spatial settings (urban, rural and peri-urban) to identify microbicide acceptability and how product associations of microbicides can influence future HIV prevention choices. Six participatory workshops using participatory action research with art-based activities and discussion groups were conducted in KwaZulu-Natal with 104 women from various geo-spatial locations and social status to understand microbicide acceptability and product associations. The data were analysed using thematic analysis. The study found that women's acceptability and product association of the tenofovir gel microbicide differed according to rural and urban areas. Most urban women identified confidence, sexiness and classiness as key associations that will encourage microbicide acceptability and use, while rural women identified respect, responsibility and confidence as the key product associations, with increased focus on the individual and collective family/community benefits of product acceptance and use. Urban-rural differences suggest a market segmentation that is contextualised to be locally responsive to promote HIV prevention technologies. Various sexual encounters further determined the types of HIV prevention technologies women would consider. In line with WHO's recommendation that PrEP should be an additional prevention choice for people at risk of HIV, this study underscores the importance of user engagement, understanding product associations and how this can influence product acceptability and promotion of HIV prevention technologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Govender</LastName><ForeName>Eliza M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Department of Culture, Communication and Media Studies, School of Applied Human Sciences , University of KwaZulu-Natal , Durban , South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansoor</LastName><ForeName>Leila E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdool Karim</LastName><ForeName>Quarraisha</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>a Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal , Durban , South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Department of Epidemiology, Mailman School of Public Health , Columbia University , New York , NY , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS Care</MedlineTA><NlmUniqueID>8915313</NlmUniqueID><ISSNLinking>0954-0121</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005782">Gels</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065129" MajorTopicYN="Y">Pre-Exposure Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012424" MajorTopicYN="N">Rural Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020377" MajorTopicYN="N">Self Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012725" MajorTopicYN="N">Sexual Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N">South Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013383" MajorTopicYN="N">Suburban Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pre-exposure prophylaxis</Keyword><Keyword MajorTopicYN="N">market segmentation</Keyword><Keyword MajorTopicYN="N">participatory research</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27799005</ArticleId><ArticleId IdType="doi">10.1080/09540121.2016.1248349</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Afrique du Sud</li></country></list><tree><country name="Afrique du Sud"><noRegion><name sortKey="Govender, Eliza M" sort="Govender, Eliza M" uniqKey="Govender E" first="Eliza M" last="Govender">Eliza M. Govender</name></noRegion><name sortKey="Abdool Karim, Quarraisha" sort="Abdool Karim, Quarraisha" uniqKey="Abdool Karim Q" first="Quarraisha" last="Abdool Karim">Quarraisha Abdool Karim</name><name sortKey="Mansoor, Leila E" sort="Mansoor, Leila E" uniqKey="Mansoor L" first="Leila E" last="Mansoor">Leila E. Mansoor</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003B06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27799005
|texte= Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27799005" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |